blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3972999

EP3972999 - ANTI-ROR1/ANTI-CD3 BISPECIFIC BINDING MOLECULES [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  15.06.2023
Database last updated on 18.11.2024
FormerRequest for examination was made
Status updated on  25.02.2022
FormerThe international publication has been made
Status updated on  27.11.2020
Formerunknown
Status updated on  19.06.2020
Most recent event   Tooltip18.03.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Velosbio Inc.
11045 Roselle Street Suite 130
San Diego CA 92121 / US
[2022/13]
Inventor(s)01 / WATKINS, Jeffry D.
c/o VelosBio Inc. 11045 Roselle Street Suite 130
San Diego, California 92121 / US
02 / JESSEN, Katti
c/o VelosBio Inc. 11045 Roselle Street Suite 130
San Diego, California 92121 / US
03 / KO, Mira
c/o VelosBio Inc. 11045 Roselle Street Suite 130
San Diego, California 92121 / US
04 / LANNUTTI, Brian
c/o VelosBio Inc. 11045 Roselle Street Suite 130
San Diego, California 92121 / US
05 / VO, Thanh-Trang
c/o VelosBio Inc. 11045 Roselle Street Suite 130
San Diego, California 92121 / US
06 / WATKINS, J. Monty
c/o VelosBio Inc. 11045 Roselle Street Suite 130
San Diego, California 92121 / US
 [2022/13]
Representative(s)Merck Sharp & Dohme LLC
120 Moorgate
London EC2M 6UR / GB
[N/P]
Former [2022/13]Böhles, Elena
Merck Sharp & Dohme Corp.
120 Moorgate
London, EC2M 6UR / GB
Application number, filing date20732061.522.05.2020
[2022/13]
WO2020US34281
Priority number, dateUS201962852039P23.05.2019         Original published format: US 201962852039 P
[2022/13]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020237173
Date:26.11.2020
Language:EN
[2020/48]
Type: A1 Application with search report 
No.:EP3972999
Date:30.03.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 26.11.2020 takes the place of the publication of the European patent application.
[2022/13]
Search report(s)International search report - published on:EP26.11.2020
ClassificationIPC:C07K16/28
[2022/13]
CPC:
C07K16/2803 (EP,KR); C07K16/2809 (EP,KR,US); A61P35/00 (EP,KR);
A61K2039/505 (KR); C07K2317/31 (EP,KR,US); C07K2317/35 (EP,US);
C07K2317/526 (EP,US); C07K2317/55 (EP,US); C07K2317/565 (EP,US);
C07K2317/622 (EP,KR,US); C07K2317/624 (EP,US); C07K2317/64 (EP,US);
C07K2317/70 (EP); C07K2317/73 (EP,KR,US); C07K2317/77 (EP,US);
C07K2317/92 (EP,KR,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/13]
Extension statesBA23.12.2021
ME23.12.2021
Validation statesMA23.12.2021
MD23.12.2021
TN23.12.2021
TitleGerman:ANTI-ROR1/ANTI-CD3-BISPEZIFISCHE BINDUNGSMOLEKÜLE[2022/13]
English:ANTI-ROR1/ANTI-CD3 BISPECIFIC BINDING MOLECULES[2022/13]
French:MOLÉCULES DE LIAISON BISPÉCIFIQUES ANTI-ROR1/ANTI-CD3[2022/13]
Entry into regional phase23.12.2021National basic fee paid 
23.12.2021Designation fee(s) paid 
23.12.2021Examination fee paid 
Examination procedure15.12.2021Amendment by applicant (claims and/or description)
23.12.2021Examination requested  [2022/13]
23.12.2021Date on which the examining division has become responsible
14.06.2023Despatch of a communication from the examining division (Time limit: M06)
24.11.2023Reply to a communication from the examining division
Fees paidRenewal fee
21.03.2022Renewal fee patent year 03
21.03.2023Renewal fee patent year 04
18.03.2024Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[XI]WO2016055592  (ENGMAB AG [CH]) [X] 1,2,16,17,19-26,28,29,31-45 * page 9, lines 9-15; figure 1; examples 4-10 * [I] 3-15,18,27,30;
 [XI]WO2017127499  (JANSSEN BIOTECH INC [US]) [X] 1,2,16,17,19-26,28,29,31-45 * figures 6,8,13; tables 13-18 * [I] 3-15,18,27,30;
 [AD]US2017233472  (BARAT BHASWATI [US], et al) [AD] 1-45 * paragraph [0244]; figures 12,23-28 *;
 [A]WO2019084060  (SILVERBACK THERAPEUTICS INC [US]) [A] 1-45 * sequences 362,367 *;
 [XI]  - JUNPENG QI ET AL, "Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (20180529), vol. 115, no. 24, doi:10.1073/pnas.1719905115, ISSN 0027-8424, pages E5467 - E5476, XP055715663 [X] 1,2,16,17,19-26,28,29,31-45 * figures 1-8 * [I] 3-15,18,27,30

DOI:   http://dx.doi.org/10.1073/pnas.1719905115
 [A]  - SATYEN HARISH GOHIL ET AL, "An ROR1 bi-specific T-cell engager provides effective targeting and cytotoxicity against a range of solid tumors", ONCOIMMUNOLOGY, (20170517), doi:10.1080/2162402X.2017.1326437, page e1326437, XP055500395 [A] 1-45 * figure 1B *

DOI:   http://dx.doi.org/10.1080/2162402X.2017.1326437
by applicantUS2017233472
 US9856327
 US2018369406
    - AL-LAZIKANI et al., JMB, (19970000), vol. 273, pages 927 - 948
    - MACCALLUM et al., J. Mol. Biol., (19960000), vol. 262, pages 732 - 745
    - LEFRANC et al., Dev Comp Immunol., (20030000), vol. 27, no. 1, pages 55 - 77
    - HONEGGERPLUCKTHUN, J Mol Biol, (20010000), vol. 309, no. 3, pages 657 - 70
    - HONEGGERPLUCKTHUN, JMol Biol, (20010000), vol. 309, no. 3, pages 657 - 70
    - TUNNACLIFFE et al., International Immunology, (19890000), vol. 1, pages 546 - 550
    - WANG et al., Cell, (20180000), vol. 9, no. 1, pages 63 - 73
    - BRINKMANNKONTERMANN, MABS, (20170000), vol. 9, pages 182 - 212
    - ZHANG et al., Am J Pathol., (20120000), vol. 181, no. 6, pages 1903 - 10
    - DANESHMANESH et al., LeukLymphoma, (20130000), vol. 54, no. 4, pages 843 - 50
    - DAVE et al., PLoS One, (20120000), vol. 7, page e52655
    - CHOI et al., Cell Stem Cell, (20180000), vol. 22, pages 951 - 959
 WO2013US32572
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.